Early adopters are using the model for diverse applications, such as auto-clipping highlights from live sports, which ...

Eikon Therapeutics has raised $381 million from its IPO, at the top end of its expectations, in another sign of a pickup in appetite for new biotech listings on the Nasdaq. The South San Francisco ...

MILLBRAE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to ...

Investing.com - JPMorgan initiated coverage on Eikon Therapeutics Inc. (NASDAQ:EIKN) with an Overweight rating and set a price target of $29.00, analyst Brian Cheng said Monday. The target represents ...

Investing.com -- Eikon Therapeutics Inc. (NASDAQ:EIKN) shares fell 5.7% following Wedbush analyst Robert Driscoll’s initiation of coverage with an Underperform rating and a $7.00 price target. The ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon Therapeutics increased the ...

Eikon Therapeutics shares were down 6%, at $16.90, in the stock's first day of trade on the Nasdaq Global Select Market. Shares of the clinical-stage biopharmaceutical company began trading midday ...

Feb 5 (Reuters) - Drug developer Eikon Therapeutics , headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.3% below their offer price in their Nasdaq ...

Despite progress made in cancer immunotherapy, some patients don’t respond to these treatments or they stop responding after a period of time. Eikon Therapeutics’ lead drug candidate could address ...

Shares of Eikon Therapeutics are set to begin trading Thursday after the clinical-stage biopharmaceutical company's upsized initial public offering was priced at the top of expectations. Eikon late ...